Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation

You may also be interested in...



Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria

TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code

Merck Tagged With Non-compliance In Japan For 3,600 Physicians' Unjustified Honoraria

TOKYO - Merck & Co. Inc - known as MSD in Japan - is trying to remediate internal oversight measurers quickly after it received a "strict warning" from an independent compliance council for improper payments to a total of 3,604 physicians in Japan between January 2009 and December 2010, which constituted violations of the Fair Competition Code

RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year

SHANGHAI - As China rolls out its 12th five-year economic development plan, the R&D-based Pharmaceutical Association Committee (RDPAC) - an industry association representing multinational biopharma companies in China - is suggesting a friendlier regulatory environment for foreign companies

Latest News
See All
UsernamePublicRestriction

Register

SC078139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel